ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0523

Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members

Medha Barbhaiya1, Doruk Erkan2, Stephane Zuily3, Tektonidou Maria4 and Surya Seshan5, 1Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY, 2Hospital for Special Surgery, New York, NY, 3Nancy Academic Hospital, Vandoeuvre-l�Nancy, France, 4National and Kapodistrian University of Athens, Athens, Greece, 5Weill Cornell Medical College, New York, NY

Meeting: ACR Convergence 2020

Keywords: antiphospholipid syndrome, Renal

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 7, 2020

Title: Antiphospholipid Syndrome Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Antiphospholipid antibody (aPL)-associated nephropathy (aPL-N) is recognized as a distinct complication of APS. However, it remains unclear whether pathologists worldwide use uniform diagnostic criteria to distinguish aPL-N from other forms of thrombotic microangiopathy. In parallel with international efforts to develop new classification criteria for antiphospholipid syndrome (APS), we conducted a pilot study to assess the renal pathologic features used by academic pathologists to diagnose aPL-N.

Methods: We conducted a web-based survey of 780 members of an international Renal Pathology Society in 50 countries. We asked respondents to determine whether two acute and eight chronic aPL-N features were consistent with acute or chronic aPL-N without providing aPL serology. and rate each item using a Likert scale (from +5 to -5): “Please consider two renal biopsies which are exactly the same except that one has the pathologic feature presented below and the other does not. Please rate how specific each feature is in differentiating “acute” or “chronic” aPL nephropathy from other diagnoses. They were also asked to rate their confidence in diagnosing aPL nephropathy on renal biopsy in two scenarios: 1) without aPL laboratory test results, or 2) with known lupus.

Results: Survey response rate was 14% (111/780) and 91% of participants self-identified as renal pathologists from 33 countries and in clinical practice for a mean (SD) of 19.1 (15.1) years. Over 92% of respondents agreed that thrombotic microangiopathy lesions in the glomeruli, arterioles, or arteries were consistent acute aPL-N, and >75% gave a positive Likert scale score ( >0), with >50% indicating Likert score +3 to +5. For chronic aPL-N, >83% agreed with the pathologic features of organized arterial or arteriolar microthrombi with or without recanalization, organized glomerular thrombi, and fibrous and fibrocellular (arterial or arteriolar) occlusions, and >50% indicated a positive Likert score ( >0), while there was less consensus for other chronic features (Table). The majority of respondents (76%) reported either an equivocal (Likert score of 0, 18%) or lack of confidence (score from -1 to -5, 58%) in diagnosing aPL-N on renal biopsy without of aPL laboratory test results. However, 80% indicated confidence (Likert score >0) in diagnosing aPL-N with concomitant lupus (69%) indicated Likert score +3 to +5.

Conclusion: Consensus exists among over 90% of pathologists worldwide that the following renal pathologic features are most specific for aPL-N: 1) non-inflammatory glomerular or small arterial microthrombi and 2) organized microvascular thrombi with recanalization. However, in the absence of serologic aPL status, over 75% of pathologists indicated lack of specificity of chronic glomerular or small arterial changes for aPL-N. Over 80% of pathologists indicated high confidence in diagnosing aPL nephropathy in patient with concomitant lupus. These findings indicate the importance of aPL serologic test results in biopsy interpretation and suggest higher specificity for certain acute or chronic features.


Disclosure: M. Barbhaiya, None; D. Erkan, None; S. Zuily, None; T. Maria, None; S. Seshan, None.

To cite this abstract in AMA style:

Barbhaiya M, Erkan D, Zuily S, Maria T, Seshan S. Characterization of Antiphospholipid Antibody-Associated Nephropathy: An International Survey of Renal Pathology Society Members [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/characterization-of-antiphospholipid-antibody-associated-nephropathy-an-international-survey-of-renal-pathology-society-members/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characterization-of-antiphospholipid-antibody-associated-nephropathy-an-international-survey-of-renal-pathology-society-members/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology